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Abstract
Caffeine is the most commonly consumed drug in the world. Although its effects are
relatively mild when consumed in moderate amounts, there exist cases where caffeine use
is problematic. Currently no behavioral intervention for problematic caffeine
consumption exists in which caffeine use is verified beyond self-reports. No measures of
caffeine dependence and withdrawal exist either. The current study examined the
viability of contingency management, an empirically supported behavioral intervention
for reducing drug use, for initiating abstinence from caffeine consumption among college
students of varying levels of use, as well as validity evidence for novel measures of
caffeine dependence and withdrawal. Participants (N = 39) came in to the lab for 3
experimental sessions in an ABA design over the course of 5 to 7 days to complete the
AUTOC, CWS, and SCEWS and to provide saliva samples. During the BAT participants
could earn a higher magnitude reward ($20) for abstaining from caffeine. 95% of
participants met criteria for abstinence during the BAT. The ELISA appeared to work at
an aggregate level, though individual samples were inconsistent enough to prevent these
results from being used as a criterion for caffeine abstinence. AUTOC, CWS, and
SCEWS scores functioned moderately well for measuring caffeine dependence and
withdrawal. These results indicate CM of caffeine use may be effective for intervening
with problematic caffeine consumption.
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Introduction
Caffeine is a stimulant and the most consumed psychoactive drug in the world.
Up to 80% of adults in the United States consume caffeine on a daily basis (Julien, 2008).
Average daily caffeine intake among caffeine consumers has been estimated to be around
280 mg (Gilbert, 1984). Caffeine consumption typically occurs relatively consistently
throughout the span of a lifetime; however little is known about its long term effects
(James, 2004). It is naturally occurring in many foods and drinks commonly consumed in
western culture, including coffee, tea, and cocoa (i.e., chocolate). Similarly, caffeine is
added to a variety of consumable items such as soft drinks, energy drinks, gum, and soap,
and is included as an ingredient in various over the counter and prescription drugs. In the
United States caffeine is most frequently consumed in coffee and soda (Hughes &
Oliveto, 1997).
Caffeine reaches peak blood concentration in 30 to 45 min. Caffeine’s half-life
varies as a function of individual factors, ranging from 2.5 to 10 hr, and it is longer for
infants, pregnant women, and elderly persons (Julien, 2008). Once in the bloodstream,
caffeine exerts excitatory effects as an adenosine antagonist. Adenosine is thought to
build up during wakefulness, ultimately contributing to feelings of fatigue. By blocking
adenosine receptors, caffeine causes an alleviation of sleepiness (Carlson, 2011).
Caffeine consumption, at both high and low doses, has been associated with
increased alertness if consumed during low levels of arousal (e.g., early morning;
Nawrot, Eastwood, Rotstein, Hugenholtz, & Feeley, 2003). Wesensten, Killgore, and
Balkin (2005) demonstrated that a single large dose of caffeine (600 mg) administered to
adults (N = 48) under 85 hr sleep deprivation improved response time on a simple
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vigilance task. Similarly, Smith (2009) showed that a single administration of chewing
gum containing a small amount of caffeine (40 mg) to college students (N = 118) led to
significantly better performance on reaction tasks compared to those who consumed
regular chewing gum or no gum.
Other subjective effects of caffeine are not as clearly established. For example,
regular caffeine consumers may demonstrate greater improvements in memory and
visiospatial reasoning (Jarvis, 1993; Smith, Sturgess, & Gallagher, 1999), although some
research has shown caffeine to have no effect on memory or even negative effects (e.g.,
Erikson et al., 1985; Terry and Phifer, 1986). Not surprisingly Goldstein, Kaizer, and
Warren (1965) found that self-reported effects of caffeine on alertness task performance
did not correlate with actual performance, indicating that subjective self-reports of
caffeine’s affects may not be valid indicators of the actual behavioral effects of the drug.
As such, subjective effects of caffeine have also been examined independently of
behavioral effects. Because many people have experience with caffeine and its effects,
there is often an expectancy effect associated with the drug. Oei and Hartley (2005) told
participants they would be consuming caffeine or placebo prior to actually consuming
one of either caffeinated or decaffeinated coffee. Participants who were told they had
consumed caffeine made more correct detections in a signal detection task than those
participants who were told they had consumed placebo, regardless of what they actually
consumed.
Most desirable effects of caffeine (e.g., increased alertness) occur following
consumption of small doses (e.g., less than 200 mg). Consuming larger quantities of
caffeine (e.g., greater than 300 mg), however, is typically associated with the onset of
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adverse symptoms, including nervousness and anxiety (Strain, Mumford, Silverman, &
Griffiths, 1994). Research has suggested that administration of larger doses of caffeine
(e.g., greater than 200 mg) is associated with increased anger and decreased drowsiness
(Roache & Griffiths, 1987), although others have found no effect (Swift & Tiplady,
1988). Likewise, research shows that large doses (e.g., 1 g; Nawrot et al., 2003) of
caffeine can produce anxiety in adults with anxiety disorders (Nawrot et al., 2003; Bruce,
Scott, Shine, & Lader, 1982). Caffeine is also related to an increase in time taken to fall
asleep as well as overall duration of sleep (Brenesova, Oswald, & Loudon, 1975).
Most research has focused on the acute effects of caffeine however there are some
notable findings related to the long-term effects of caffeine consumption. Caffeine is
associated with an increase in occurrence of reproductive complications when consumed
in doses of 400 mg or more daily during pregnancy (e.g., SIDS; Ford et al., 1998), as well
as with accelerated decrease in bone density among post-menopausal women who
consume more than 450 mg daily (Harris & Dawson-Hughes, 1994). There is also an
established relation between regular caffeine consumption and elevated blood pressure
(James, 2004). At the population level, any increases in high blood pressure (including
those attributed to regular caffeine consumption) are usually associated with increased
rates of cardiovascular disease (James, 2004), though the link between regular caffeine
consumption and cardiovascular disease is unknown. Additionally, long-term caffeine
use may lead to a dependence syndrome analogous to other substance use disorders
described in the DSM-IV-TR (APA, 2000). Although not formally recognized in the
DSM-IV-TR as a substance of abuse, caffeine can lead to intoxication, withdrawal, and
dependence according to the literature (e.g., Strain et al., 1992). Symptoms of
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intoxication (also referred to as caffeinism; Greden, 1974) include exaggerated
experience of caffeine withdrawal effects, including nervousness, irritability, agitation,
and headache (Greden, 1974). Rates of excessive caffeine use leading to intoxication
among psychiatric inpatients may be as high as 40% (MacKay & Rollins, 1989);
however, rates of caffeinism in the population are uncertain due to underdiagnoses
(Greden, 1974).
Caffeine dependence and withdrawal
According to the DSM-IV-TR, drug use must meet at least three of the following
seven criteria to be considered drug dependence (relevant examples with caffeine
included in parentheses): (a) tolerance (Griffiths & Woodson, 1988); (b) withdrawal
(Silverman, Evans, Strain, & Griffiths, 1992); (c) substance often taken in larger amounts
over a longer period of time than intended (Greden, 1974); (d) persistent desire or
unsuccessful efforts to cut down or control use (Greden, 1974); (e) a great deal of time
spent in activities necessary to obtain, use, or recover from the effects of the substance
(Strain et al., 1994); (f) important social, occupational, or recreational activities given up
or reduced because of substance use; (g) continued use despite knowledge of a permanent
or recurrent physical or psychological problem that is likely to have been caused or
exacerbated by substance use (Greden et al., 1978). Data have shown that caffeine use
can lead to a situation in which an individual meets criteria for dependence (Hughes,
Oliveto, Liguori, Carpenter, & Howard, 1998).
Caffeine dependence has been scarcely studied explicitly but research has yielded
data that support the notion that dependence can and does occur. Several efforts have
been made to characterize caffeine dependence among caffeine users. Strain, Mumford,
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Silverman, and Griffiths (1994) examined 99 adults who self-reported psychological and
physical dependence on caffeine. The authors used a structured clinical interview that
included assessment of caffeine dependence based on DSM-IV (APA, 1994) criteria for
substance dependence. Strain et al. (1994) found that 16 participants met criteria for
caffeine dependence. Hughes, Oliveto, Liguori, Carpenter, and Howard (1998) reported
prevalence of caffeine dependence criteria among a sample of 162 caffeine users via
telephone interviews. Using DSM-IV criteria for substance dependence, Hughes et al.
(1998) found a substantial proportion of participants self-reported experiences consistent
with meeting criteria for caffeine dependence. Taken together with Strain et al. (1994)
and other research on the potential for caffeine abuse (e.g., Ogawa & Ueki, 2007;
Bernstein, Carroll, Thuras, Cosgrove, & Roth, 2002), these results provide compelling
evidence for caffeine dependence.
An aspect of dependence that is of particular interest with respect to caffeine is
withdrawal (e.g., Juliano & Griffiths, 2004). The greatest occurrence of undesirable
effects of caffeine consumption occurs following cessation of use. Indeed, the effects of
caffeine vary by latency since last consumption (Yeomans et al., 2002; Addicott &
Laurienti, 2009; Christopher, Sutherland, & Smith, 2005), suggesting that many of the
appetitive effects of caffeine are due to relief of caffeine withdrawal. Onset of withdrawal
symptoms varies but generally occurs around 12 hr after last caffeine consumption
(Griffiths & Woodson, 1988), with peak intensity of withdrawal symptoms occurring at
20 to 50 hr after last consumption (Juliano & Griffiths, 2004), continuing with
progressively severity for 2 to 9 days (McKim, 2007). Symptoms are quickly alleviated
by consuming caffeine (Julien, 2008; Juliano & Griffiths, 2004).
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Juliano and Griffiths (2004) conducted a comprehensive review of the literature
on caffeine withdrawal and found that headache was the most common symptom of
withdrawal. Fatigue, decreased energy and activity, decreased alertness, drowsiness,
decreased well-being, depressed mood, decreased concentration, irritability, and
fogginess also met the authors’ criteria for valid symptoms of caffeine withdrawal.
Despite evidence for caffeine dependence and withdrawal, there currently exists
no standardized method for measuring these phenomena. Taken together, their lack of
specific inclusion in the DSM-IV-TR (APA, 2000) and the fact that caffeine is a legal,
widely available drug, among other potential reasons, limit the perceived prevalence and
importance of caffeine dependence and withdrawal syndromes.
Contingency management
Just as there are few tools for measuring and characterizing caffeine dependence
and withdrawal, there are fewer available treatment options, presumably because of a
relative lack of concern related to excessive caffeine consumption. Unlike many other
types of drugs (e.g., opioids, nicotine, alcohol) there are currently no effective
pharmacotherapies for stimulants, including caffeine. As such, treatment of problematic
caffeine consumption (e.g., dependence) may be best approached similarly to how
dependence for other stimulants is treated—with behavioral interventions. Behavioral
interventions involve manipulation of environmental variables that influence drug use,
such as drug cost or availability (Bickel, Madden, & Petry, 1998), in order to decrease or
cease drug consumption.
Contingency management (CM) has been a well-studied behavioral intervention
strategy. In CM interventions for substance use, participants earn access to incentives
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(e.g., money, prizes) contingent upon providing evidence of reduction or abstention from
substance use. A wide range of studies have demonstrated the feasibility of CM for
reducing use of a variety of substances (Petry, 2000), including nicotine (Roll, Higgins,
& Badger, 1996), cocaine (Silverman, Chutuape, Bigelow, & Stitzer, 1999), opiates
(Higgins, Stitzer, Bigelow, & Liebson, 1986), methadone (Iguchi, Belding, Morral, &
Lamb, 1997), alcohol (Miller, Hersen, Eisler, & Watt, 1974), marijuana (Budney, Moore,
Higgins, & Rocha, 2006), and benzodiazepines (Stitzer, Bigelow, Liebson, & Hawthorne,
1982).
Recent meta-analyses support the efficacy of CM and suggest that the effect sizes
for CM interventions consistently exceed other treatment options for substance
intervention (i.e., Lussier, Heil, Mongeon, Badger, & Higgins, 2006; Prendergast, Podus,
Finney, Greenwell, & Roll, 2006; Dutra et al., 2008). Few studies to date have examined
the efficacy of CM for intervening with caffeine use.
Several studies have applied CM to caffeine use; however, there are several
critical deficits that suggest a need for further study. Foxx and Rubinoff (1979)
investigated the utility of an incentive-based behavioral procedure for reducing excessive
coffee drinking among three normal-functioning adults who self-reported interest in
reducing their coffee drinking and consuming at least eight cups of brewed coffee per
day. A changing criterion design (Hartmann & Hall, 1976) was implemented to reduce
caffeine consumption to the equivalent of five cups of coffee or fewer over the course of
4 weeks. Coffee drinking was monitored via participant self-report and self-reports from
a significant other who frequently interacted with the participant and was familiar with
the participant’s coffee drinking. Overall, the changing criterion design reduced coffee
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drinking to moderate levels of use: Two participants never exceeded criterion levels of
caffeine consumption and the third participant only exceeded criterion on 2 days (Foxx &
Rubinoff, 1979). Follow-up at 40 months indicated participants continued to consume
fewer than the terminal criterion goal of the initial study (Foxx, 1982). Bernard,
Dennehy, and Keefauver (1981) performed a systematic replication of Foxx and Rubinoff
(1979) in a single-case research procedure and yielded similar results. Although
seemingly compelling, caffeine consumption was not verified beyond self-report, a key
component of CM.
James, Stirling, and Hampton (1985) studied 27 adults who consumed at least
eight cups of coffee or tea daily. Participants provided self-reports of caffeine
consumption supplemented by independent reports of caffeine consumption by
significant others. Participants were assigned to either a self-initiation regimen (i.e., an
active treatment control group) or a fading procedure, with criterion determined based on
individual levels of consumption. Participants in the fading group reduced consumption
the most from baseline and maintained lowest consumption levels throughout treatment
and again at 6- and 18-week follow-up.
CM procedures are effective for initiating and maintaining reduced caffeine
consumption (Foxx & Rubinoff, 1979; Bernard et al., 1981; James et al., 1985).
However, findings from studies to date are significantly limited in their reliance on selfreport for verification of meeting criterion levels of caffeine use and lack of verification
of caffeine use or abstinence. Additionally, CM can be costly to implement in terms of
funding, researcher time, and the relatively high behavioral cost for participants.
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The brief abstinence test
A brief abstinence test (BAT) can be used to model CM and to induce abstinence
for a short period of time in effort to examine potential for efficacy (Robles et al., 2000).
Participants in a BAT receive high-magnitude incentives contingent on providing
evidence (self-report and biological samples) of brief (i.e., hours, or days) drug
abstinence. Further, the BAT allows for experimental manipulation of use such that
abstinence and related phenomena, such as withdrawal, may be examined. As such, a
BAT is an ideal method for preliminary analysis of the potential efficacy of CM for
caffeine use. The BAT has been used to initiate abstinence from opiates among opiate
and cocaine dependent community adults (Sigmon, Correia, & Stitzer, 2004; Robles et
al., 2000) as well as among nicotine dependent college student smokers (Irons & Correia,
2008).
Robles et al. (2000) evaluated the effectiveness of brief abstinence test for cocaine
among cocaine-dependent methadone maintenance outpatients. Seventy-two participants
enrolled in a 13-week methadone maintenance program were informed at the beginning
of week 9 that if they returned in 2 days and had abstained from cocaine use since the
beginning of the week that they would earn a $100 voucher. Participants who met
abstinence criteria received payment 2 days after providing urine samples for analysis.
No new use of cocaine was assumed by either a low benzoyclecgonine concentration
(i.e., ≤ 300 ng/ml) analyzed from a frozen urine sample or a minimum 50% reduction in
benzoyclecgonine concentration in the sample. Among those participants with complete
data sets (n = 50), abstinence during BAT (84%) was significantly greater than abstinence
during days prior to and immediately following the test date. Results demonstrated that
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combining a high value reinforcer ($100) with a low cost behavioral requirement (i.e.,
abstinence from cocaine use for 2 days) yielded clinically significant rates of substance
abstinence, particularly when compared to abstinence rates prior to and following the
intervention. These results provide evidence for the utility of a brief abstinence
reinforcement procedure for reliably initiating drug abstinence.
Katz et al. (2002) obtained results similar to Robles et al. (2000) that
demonstrated the utility of a BAT. They extended the findings of Robles et al. (2000) via
systematic replication and by introducing two new payment conditions, each of which
included subsequent payments for additional periods of brief drug abstinence. Katz et al.
(2000) used a within-subjects design in which participants experienced one of four
conditions in counterbalanced order, each separated by 4 weeks of a “washout period,”
over 23 weeks. In addition to the control and single voucher conditions used in Robles et
al. (2000), Katz et al. (2002) included both a continuous and an interrupted voucher
schedule, each of which offered reinforcers over more prolonged time periods ($300
total) compared to Robles et al. (2000). All three experimental conditions produced
significantly higher rates of abstinence than the control condition; additionally, the
continuous and interrupted voucher conditions produced higher prolonged rates of
abstinence than the control and single voucher conditions, neither of which differed in
abstinence rate by the end of the 11-day experimental period. These results demonstrate
that a BAT can not only initiate abstinence but that the initial abstinence experience can
show influence on use in subsequent sessions during which response requirements are
more difficult to reach.
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Sigmon, Correia, and Stitzer (2004) examined the generalizability of repeated
occurrences of abstinence initiation during a BAT to periods for which no incentives
were available contingent upon drug abstinence. Their results further demonstrated the
effectiveness of a BAT for reliably initiating cocaine abstinence among methadone
patients. Participants in each of two experimental groups provided significantly more
cocaine-negative urine samples on earning days compared to non-earning days.
Irons and Correia (2008) extended the application of a BAT to another pattern of
drug use and to a different population. They used a 3-week ABA-design intervention in
which 12 college students could earn a substantial monetary reward ($65) contingent on
providing self-reports indicative of abstinence from smoking and negative urine
(urinalysis) and breath (CO levels indicative of abstinence) samples of nicotine.
Participants returned to the lab 1 week following an initial baseline phase for the BAT
and again 1 week after that for a return to baseline session. Overall, both mean urinalysis
and CO levels, as well as self-reported measures of abstinence, significantly decreased
from baseline to the BAT, indicating the generalizability of a BAT to multiple drugs and
to different populations. However, none of these measures returned to original baseline
levels at the return to baseline session. Although the causal relation between the BAT and
change in smoking behavior was confounded by the inconsistent rates of behavior across
baselines, a failure to return to baseline rates of smoking may represent a clinically
significant pattern of behavior resulting from the intervention. Being able to initiate
continued lower levels of drug use is significant from a clinical perspective for which the
goal of intervention is to reduce or eliminate drug use. As such, more research is
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necessary to assess further utility of a BAT as a clinical intervention for initiating (and
possibly maintaining) drug abstinence.
The current study
The purpose of the current study was to examine the potential viability of CM (via
use of a BAT) for experimentally inducing caffeine abstinence long enough to induce
peak experience of withdrawal symptoms (i.e., 2 days abstinence) among college
students. Part of examining the viability of CM for caffeine use includes assessing the
utility of an ELISA for verifying caffeine use in saliva: The current study therefore
supplemented self-reports of caffeine use with saliva samples in order to examine the
potential of verifying behavior with a biological measure. A secondary goal included
examining the validity of novel measures of caffeine dependence and caffeine
withdrawal. Based on previous research, I hypothesized that when offered incentives to
abstain, caffeine consumption would decrease among participants. I also hypothesized
that experience of caffeine withdrawal symptoms would be greater following abstinence
relative to following regular consumption. Finally, I hypothesized that scores on a novel
measure of caffeine dependence would be positively correlated with baseline levels of
caffeine consumption.

Method
Participants
Inclusion criteria. Participants were 39 undergraduate students (Mage = 19.41, SD
= 0.94, 74% female, 95% White) enrolled at JMU who were at least 18 years of age, selfreported consuming at least 25 mg caffeine per day (M = 122.73, SD = 116.08), and who
did not currently take any prescription medications that contain caffeine during the study.
A power analysis using G*Power revealed a minimum sample size of 7 to detect an effect
using the effect size for CM (d = 0.58) obtained by Dutra et al. (2008) with moderate
power set to .80 for α = .05.
Recruiting procedures. Participants were recruited from the pool of respondents
to a central screener that was emailed to the entire student body at James Madison
University (JMU) during the fall semester. The central screener consists of 21
questionnaires about various health-related topics. Respondents were invited 40 to 60 at a
time to participate in an enrollment session during which inclusion criteria were verified.
During the enrollment session, those respondents that met all inclusion criteria were
invited to participate in the current study.
Materials
Demographics questionnaire. A demographics questionnaire was used to assess
demographic information of the participants, including age, gender, and race.
Daily Caffeine Consumption Questionnaire (DCCQ). This questionnaire was
used to obtain participants’ self-reported use of caffeine. Three researcher-generated
items were included to characterize most recent consumption of caffeine. The DCCQ
includes the Caffeine Consumption Questionnaire (Landrum, 1992), a measure developed
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to precisely and consistently assess caffeine use among college students by accounting
for the number of days and servings that an individual consumes various foods and
beverages containing caffeine.
Autonomy Over Caffeine Scale (AUTOC). Currently there is no standard
measure of dependence for caffeine. The AUTOC measure was adapted from the
Autonomy Over Smoking Scale (AUTOS; DiFranza et al., 2009) that was developed
from DSM-IV-TR (APA, 2000) criteria for smoking dependence. The AUTOC includes
the same 12 items as the AUTOS except wording was altered from tobacco consumption
to reflect caffeine consumption. The AUTOS is used to assess current tobacco
withdrawal symptom intensity that represents autonomy, or lack thereof, from nicotine.
Items are descriptions of experiences of smoking withdrawal symptoms to which the
participant records how well each describes themselves; responses are recorded on 4point Likert scales (0 = not at all, 3 = very well). Scores can range between 0-36, with
higher scores corresponding to increased experience of withdrawal symptoms, cueinduced cravings, and psychological dependence. The AUTOS is highly internally
reliable (α = .91 - .97) and is concurrently valid with Hooked On Nicotine Checklist
scores (DiFranza et al., 2002) and DSM-IV TR (APA, 2000) diagnostic criteria for
nicotine dependence.
Caffeine Withdrawal Scale (CWS). Currently there is no standard measure for
assessing experience of symptoms of withdrawal from caffeine. This measure was
adapted from the Wisconsin Smoking Withdrawal Scale (WSWS; Welsh et al., 1999) that
was developed to assess severity and type of smoking withdrawal symptoms. The CWS
includes 23 of the same 28 items as the WSWS except wording was altered from
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descriptions of smoking withdrawal symptoms to reflect those of caffeine withdrawal,
and five items relating to food consumption were removed. Items on the WSWS consist
of statements related to clinical symptoms of smoking withdrawal (e.g., “I have felt
impatient”) and are rated on a 5-point Likert-type scale (1 = strongly disagree, 5 =
strongly agree). The WSWS provides an overall withdrawal score [range = 0 (no
withdrawal) – 140 (extreme withdrawal)] and scores for each of its 7 subscales, which
reflect clinical symptoms of nicotine withdrawal: anger, anxiety, sadness, concentration,
craving, sleep, and hunger (APA, 1994). Internal consistency for measuring overall
withdrawal is high (α = .90 - .91), whereas subscale internal consistencies are slightly
lower (α = .75 - .93). Additionally, overall measures on the WSWS are predictive of
smoking cessation outcomes (Welsch et al., 1999).
Stimulant and Caffeine Experience of Withdrawal Symptoms (SCEWS).
There are currently no standard criteria for measuring symptoms of caffeine withdrawal.
This measure was created using summaries of symptoms of caffeine withdrawal reported
by Julien (2008) and McKim (2007), as well as DSM-IV TR criteria for withdrawal from
small doses of another relatively mild stimulant, amphetamine withdrawal syndrome
(APA, 2000). Criteria for another stimulant (amphetamine) other than caffeine were used
because the DSM-IV-TR does not include caffeine withdrawal symptoms.
Enzyme-linked immunosorbent assay (ELISA). A caffeine ELISA (Neogen
Corporation, Lexington, KY) was used to validate self-reported measures of caffeine
consumption by revealing the presence of caffeine metabolites in saliva samples. After
samples are obtained, they will be frozen at -40°C until enough samples are collected to
run a single ELISA (up to 45 samples, each in duplicate and including controls, can be

16
analyzed at once). Once enough samples have been collected, they are thawed and
assayed. During an incubation period, samples are placed in dishes pre-coated with
binding sites. Following incubation the dishes are washed and K-Blue® Substrate is
added to the dish; the antibodies from the substrate and drug (i.e., caffeine) molecules
compete for binding sites on the dish. Approximately 30 min after incubation with the
substrate the samples may be analyzed using a spectrophotometer; color change is
inversely related with the presence of the drug metabolite in the sample. Results are
presented as a logarithmic function of light absorbance at 450 nm.
Design
The current study was an ABA reversal design. Following enrollment,
participants experienced a baseline condition. All participants then experienced a BAT 2
days after the baseline session, followed by a return to baseline 2 to 4 days after the BAT
session.
Procedure
All sessions occurred between 12:30 p.m. and 6:30 p.m. in a psychology research
lab.
(A) Baseline 1/Enrollment. All participants earned a $10 voucher for attending
and completing the Baseline 1/enrollment session. This session included verification of
inclusion criteria (see above) by oral report, followed by informed consent procedures,
and collection of self-report measures (DCCQ, AUTOC, CWS, and the SCEWS) and a
saliva sample. Participants were informed that if they returned to the lab 2 days following
this initial session and demonstrated evidence of abstinence (saliva sample indicative of
abstinence AND self-report not consuming any caffeine) that they would earn $20, and
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that if they returned to the lab 2 days following this initial session and provided
biological and self-report measures but failed to demonstrate evidence of abstinence they
would earn $2. Participants were told that any caffeine use would result in a failed
biological test.
(B) Brief Abstinence Test (BAT). Participants returned to the lab 2 days
following the Baseline 1 session and completed the self-report measures and provided a
saliva sample. The researcher asked participants if they abstained from caffeine since
Baseline 1 and then asked probing questions about the experience. Participants who
demonstrated abstinence were provided a $20 voucher. Participants who did not
demonstrate abstinence were provided a $2 voucher for attendance. Participants were
then asked to return to the lab for a return to baseline session for which they could earn
$5 for attendance, regardless of their caffeine consumption prior to the session, and a $10
bonus for completing all three sessions with perfect attendance.
(A) Baseline 2. A final session occurred 2 days following the BAT phase and it
included completion of the self-report measures and a saliva sample. Participants earned
$5 for attending the session and a $10 bonus for perfect attendance to all three sessions.
Participants were able to earn a maximum of $45 if they attended all sessions and
achieved abstinence criteria during the BAT. The time period for the study for individual
participants was between 5 to 7 days (Baseline 2 occurred 2 to 4 days after the BAT,
depending on the day of the week of the BAT). All participant payments were made in
the form of vouchers until the end of the experiment so that the saliva samples could be
collectively analyzed using the ELISA. Participants were then instructed to return to the
lab 1 to 5 days after their final session (i.e., once the saliva samples have been analyzed)
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to receive cash payment for all sessions in one sum. Research has shown high magnitude
reinforcers are effective for changing drug use in a CM analog even at delays of 1 week
(Packer, Howell, McPherson, & Roll, 2012).

Results
Thirty-nine of 42 participants who enrolled completed all three sessions of the
experiment. One participant withdrew after completing the baseline session and reentered later. Analyses excluded data from this participant’s first baseline session as well
as data from individuals who did not complete all three sessions. Two respondents who
completed one session did not return for any further sessions and one respondent who
completed two sessions did not return for the final session; data for these three
respondents were not used in any analyses.
Abstinence during the BAT was defined as a verbal self-report of 0 caffeinated
products consumed since the baseline session supplemented with responses to probing
questions consistent with experience of withdrawal from caffeine (e.g., “I felt sleepier
during classes than usual”). Percentage of light transmittance, as measured by the ELISA,
was used as a supplement to self-reported caffeine for verifying caffeine abstinence. A
spectrophotometer analyzed all saliva samples in duplicate; as such, values of percentage
of light transmittance used for statistical analyses were mean values of each pair of
duplicate samples. In most cases percentage of light transmittance appeared to support
self-reports, though measurement error (e.g., bad wash during the rinsing process) from
the ELISA overall was too substantial to be used alone as verification of caffeine
abstinence. Well readings that seemed to be erroneous (e.g., two samples of one
replicated sample were notably different) were not excluded in analyses.
See Table 1 for a summary of descriptive statistics for the dependent measures.
See Table 2 for a summary of intercorrelations among the novel measures of caffeine
dependence and withdrawal.
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Primary analyses
Self-report. Among the 39 participants, 37 (95%) met self-report criterion for
abstinence during the BAT and 18 (46%) during Baseline 2. A repeated-measures
ANOVA revealed statistically significant differences in self-reported latency (hr) since
last consuming caffeine, F(1.05, 39.90) = 23.42, p < .001, partial η2 = .38. Planned
contrasts revealed that latency since last consuming caffeine at the BAT (M = 54.23, SD
= 14.59) and Baseline 2 (M = 49.65, SD = 56.93) sessions were significantly longer than
for Baseline 1 (M = 7.11, SD = 10.14, ps < .001). Participants who met criteria for
abstinence did not significantly differ from participants who did not meet criteria for
abstinence at either BAT or Baseline 2 in terms of self-reported average daily caffeine
consumption (ps > .05).
ELISA. Thirty-two of 39 participants (82%) met absolute reduction criterion for
abstinence during the BAT using self-report and results from the ELISA (i.e., a reduction
in caffeine use as indicated by the ELISA; no clear cutoff score was evident from the
analyses nor existed in the literature for caffeine).
Twenty-four participants (62%) met reduction criterion during the BAT using
duplicate samples SD (i.e., reduction of ≥ 1 SD for the mean difference between duplicate
samples across all three sessions). An independent t-test revealed participants who met
this reduction criterion from Baseline 1 to BAT significantly differed from participants
who did not meet this criterion in light transmittance during the BAT, t(36.76) = 4.03, p <
.001, d = 1.20, CI 95% [0.047, 0.142]. Another independent t-test revealed participants
who met this reduction criterion from BAT to Baseline 2 did not significantly differ from
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participants who did not meet this criterion in light transmittance during Baseline 2, t(37)
= 1.10, p = .280, d = 0.37, CI 95% [-0.032, 0.108].
A repeated-measures ANOVA revealed statistically significant differences in light
transmittance through the saliva samples among the three sessions, F(2, 76) = 8.36, p =
.001, partial η2 = .18. Planned contrasts revealed the BAT (M = 79.58%, SD = 9.23%)
and Baseline 2 (M = 80.16%, SD = 10.49%) yielded significantly less light transmittance
compared to Baseline 1 (M = 85.57%, SD = 6.38%, ps = .001 and .005, respectively).
Neither percentage light transmittance nor latency since last consuming caffeine differed
significantly between BAT and Baseline 2 sessions (ps = 1.0).
A median split of self-reported average daily caffeine consumption (median = 90
mg) yielded high and low caffeine users, neither of which differed in light transmittance
at Baseline 1, BAT, or Baseline 2 (ps > .05). Participants in the upper and lower quartiles
of self-reported average daily caffeine use did not significantly differ in light
transmittance at Baseline 1, BAT, or Baseline 2 (ps > .05).
Pearson Product-Moment correlations revealed no significant correlations
between light transmittance and self-reported latency since last consuming caffeine
during Baseline 1 [r(37) = -.02, p = .882], the BAT [r(37) = -.02, p = .919], or Baseline 2
[r(37) = -.22, p = .178]. A point-biserial correlation revealed that light transmittance
significantly negatively correlated with whether or not participants met criteria for
abstinence from caffeine across all three study sessions such that likelihood of meeting
criteria for abstinence from caffeine was negatively related with light transmittance,
r(117) = -.295, p = .001.
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Dependence analyses
AUTOC. Pearson Product-Moment correlations revealed AUTOC scores and
CWS scores significantly correlated during Baseline 1 [r(37) = .46, p = .003], the BAT
[r(37) = .71, p < .001], and Baseline 2 [r(37) = .72, p < .001]. Pearson Product-Moment
correlations also revealed AUTOC scores and SCEWS scores significantly correlated
during Baseline 1 [r(37) = .37, p = .020], the BAT [r(37) = .75, p < .001], and Baseline 2
[r(37) = .64, p < .001].
A repeated-measures ANOVA revealed that AUTOC scores significantly differed during
the three study sessions, F(1.66, 63.23) = 5.27, p = .011, partial η2 = .122. Planned
contrasts showed AUTOC scores increased significantly from Baseline 1 (M = 8.72, SD =
5.99) to BAT (M = 10.62, SD = 8.77, p = .023), and declined slightly from BAT to
Baseline 2 (M = 10.28, 8.46, p = 1.0). AUTOC scores did not differ significantly between
Baseline 1 and Baseline 2 (p = .098).
Pearson Moment-Product correlations revealed AUTOC scores and percentage
light transmittance were significantly negatively correlated during each Baseline 1 [r(37)
= -.34, p = .032] and Baseline 2 [r(37) = -.42, p = .008], but were not significantly
correlated during the BAT [r(37) = -.11, p = .502]. Additionally, Baseline 1 AUTOC
scores were not significantly related with self-reported average daily caffeine
consumption, r(37) = .05, p = .802. Using a median split of self-reported average daily
caffeine consumption, high and low caffeine users did not significantly differ in AUTOC
scores at Baseline 1, t(37) = 1.67, p = .104, d = 0.55, CI 95% = [-6.98, 0.68].
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Withdrawal analyses
Pearson Product-Moment correlations revealed CWS and SCEWS scores
significantly correlated during Baseline 1 [r(37) = .36, p = .024], the BAT [r(37) = .67, p
< .001], and Baseline 2 [r(37) = .58, p < .001].
CWS. A repeated-measures ANOVA revealed that CWS scores did not
significantly differ across the three study sessions, F(2, 76) = 0.56, p = .576, partial η2 =
.014. CWS scores slightly increased from Baseline 1 (M = 64.38, SD = 6.77) to BAT
(M = 65.26, SD = 8.82) and declined slightly from BAT to Baseline 2 (M = 65.15, 8.98),
though not back to Baseline 1 levels.
Using a median split of self-reported average daily caffeine consumption, high
and low caffeine users did not significantly differ in CWS scores at BAT or Baseline 2
(ps > .05).
Independent t-tests revealed participants who met reduction criterion from
Baseline 1 to BAT using duplicate samples SD significantly differed in CWS scores from
participants who did not meet this criterion during the BAT, t(37) = 2.76, p = .009, d =
0.93, CI 95% [1.95, 12.81], and likewise from BAT to Baseline 2 during Baseline 2, t(37)
= 3.21, p = .003, d = 1.12, CI 95% [3.23, 14.31].
Pearson Moment-Product correlations revealed CWS scores and percentage light
transmittance were not significantly correlated during Baseline 1 [r(37) = -.10, p = .546]
or the BAT [r(37) = .129, p = .435], but were significantly negatively correlated during
Baseline 2 [r(37) = -.33, p = .038].
SCEWS. A repeated-measures ANOVA revealed that SCEWS scores
significantly differed across the three study sessions, F(2, 76) = 6.88, p = .002, partial η2
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= .153. Scores on the SCEWS significantly increased from Baseline 1 (M = 3.05, SD =
3.04) to BAT (M = 5.00, SD = 4.48, p = .010) and significantly declined from BAT to
return to baseline (M = 2.97, SD = 3.96, p = .012). SCEWS scores did not differ across
the two baseline sessions (p = 1.0).
Using a median split of self-reported average daily caffeine consumption, high
and low caffeine users did not significantly differ in SCEWS scores at BAT or Baseline 2
(ps > .05).
Independent t-tests revealed participants who met reduction criterion from
Baseline 1 to BAT using duplicate samples SD did not significantly differ in SCEWS
scores from participants who did not meet this criterion during the BAT, t(37) = 1.03, p =
.310, d = 0.35, CI 95% [-1.47, 4.50], but SCEWS scores did significantly differ between
these groups from BAT to Baseline 2 during Baseline 2, t(13.71) = 2.64, p = .020, d =
1.20, CI 95% [1.67, 6.48].
Pearson Moment-Product correlations revealed SCEWS scores and percentage
light transmittance were not significantly correlated during Baseline 1 [r(37) = -.19, p =
.248] or the BAT [r(37) = -.02, p = .895], but were significantly negatively correlated
during Baseline 2 [r(37) = -.46, p = .003].

Discussion
The current study examined the potential efficacy of CM for initiating caffeine
abstinence among college students of varying levels of typical caffeine consumption
using a BAT, and to induce abstinence from caffeine long enough for participants to
experience peak withdrawal symptoms so that novel measures of caffeine withdrawal and
dependence could be examined. Results indicated the BAT was effective for initiating
abstinence from caffeine among participants. A majority of participants (95%) met
criteria for abstinence from caffeine when offered a high magnitude monetary incentive,
and nearly half of all participants continued to abstain from caffeine at the return to
baseline session. Scores on the novel measure of caffeine dependence, the AUTOC,
unexpectedly varied across sessions contrary to what would be expected of levels of
dependence over the course of approximately 1 week. AUTOC scores were not related to
baseline levels of caffeine consumption. Scores on one novel measure of caffeine
withdrawal, the CWS, did not systematically vary across sessions as predicted based on
the apparent success of the BAT for initiating abstinence from caffeine and thus inducing
withdrawal; however, scores on the other novel measure of caffeine withdrawal, the
SCEWS, did vary across sessions as predicted. SCEWS scores differed across sessions as
a function of whether participants met criteria for abstinence from caffeine whereas CWS
scores did not.
Aggregated results from an ELISA matched aggregated self-reported levels of
abstinence throughout the study, though results for individual samples sometimes varied
nonsystematically from self-reports. The use of an ELISA for providing a biological
measure of caffeine use was an improvement upon previous CM of caffeine studies
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which only used self-report measures to verify caffeine use (e.g., Foxx & Rubinoff,
1979); however, because individual data from the ELISA were sometimes incongruent
with self-reports it is unclear how well this technology measures caffeine use for the
purposes of the current research design. Results of the ELISA were moderately
inconsistent within and between samples. Individual factors (e.g., metabolic rate, caffeine
use prior to experimental time periods) possibly influenced ELISA results, though how
and to what degree are not clear and warrant further research. As such, ELISA results
themselves were not sufficient as a criterion for determining caffeine use in the current
study. Further research is warranted to examine exactly how these factors influence the
ELISA so that criterion values or percent change may be established to discern caffeine
abstinence over a certain period of time. Additionally, future research on caffeine
consumption would benefit from advances in technology for determining levels of
caffeine use similar to simple techniques available for smoking (e.g., urinalysis), alcohol
(e.g., breathalyzer), and other drugs. Such a technology would not only aid in caffeine
research but could also be used as a medical tool for screening caffeine consumption as a
potential contributing factor for numerous health-related problems (e.g., anxiety
symptoms, insomnia, or headaches for which there is no clear underlying cause).
Caffeine consumption reduced during the BAT but did not increase to baseline
levels during the return to baseline. Although this is a challenge to inferring a causal
relation, it is a clinically preferred outcome relative to observing a complete return to
baseline levels of behavior and one that has been reported using a BAT in the literature
(Irons & Correia, 2008). That is, to observe the success of the BAT coupled with the
continued behavior change in the desired direction (i.e., a reduction in drug use) in a
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clinical setting would likely be considered a success. Because no participants met criteria
for abstinence at baseline and 95% of participants met criteria for abstinence during the
BAT, it is unlikely that the phase changes did not exert experimental control. Despite the
apparent effectiveness of the intervention, the lack of a return to baseline levels of
behavior confounds a causal relation between the BAT and the change in caffeine
consumption. Participants may have continued to remain abstinent from caffeine because
they encountered the appetitive effects of abstinence such as the cessation of experience
of withdrawal symptoms. Future research on the BAT could use multiple baseline
designs or between-subjects designs to discern the apparent causal relation between the
BAT and changes in caffeine consumption.
If participants continued to abstain from caffeine use due to encountering the
appetitive effects of abstinence then a BAT may be an effective but also sufficient
treatment method for reducing caffeine consumption. Unlike other drugs (e.g., nicotine)
cue-induced relapse for caffeine use is likely not an important post-intervention risk.
Although past researchers (e.g., James, Stirling, & Hampton, 1985) suggested treatment
for reducing caffeine use should fading components to avoid initiating aversive
withdrawal symptoms, the observed results indicate that a single contingency is sufficient
for initiating reduced caffeine consumption. Thus a BAT may be a more cost-effective
treatment option for problematic caffeine consumption than a fading procedure or a largescale CM intervention. However, the long-term implications of reduced caffeine use
among individuals for whom caffeine consumption is problematic are not clear. Given
similarities in caffeine consumption and use of other drugs it is unlikely that the long-
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term benefits of reduced caffeine use would be less than the cost of implementing BATs
to induce the change in consumption.
Participants did not receive payment until 2 to 6 days following their final session.
Delay of delivery of contingencies did not appear to influence behavior to a greater
degree than did the experimental design. These results are consistent with those of
Packer, Howell, McPherson, and Roll (2012), who found that high magnitude reinforcers
can cause reduced drug use even when delivered at delays of up to 1 week. Two
participants did not meet criteria for caffeine abstinence during the BAT. One participant
reported that they forgot about the instructions given during Baseline 1. The other
participant who did not abstain from caffeine during the BAT reported they “needed
caffeine” because they had a test the morning of the day of the BAT session. Despite the
fact that these observed limitations were beyond experimental control, the intervention
achieved the primary goal of the study as evident by the majority of the sample who met
criteria for abstinence from caffeine. Future research on CM of caffeine consumption
could control for these specific issues by manipulating saliency of the contingencies (e.g.,
sending verbal reminders via text message or E-mail).
The novel measure of caffeine dependence and one of the novel measures of
withdrawal (CWS) were developed from analogous measures for smoking. No such
measures exist for caffeine; smoking measures were adapted for caffeine because
caffeine consumption is moderately analogous to cigarette smoking (legal, occurs over
the course of the day, effects are relatively mild, CM works for both). AUTOC scores
differed across experimental phases contrary to what would be expected of drug
dependence over such a brief period of time (e.g., cigarette dependence; DiFranza et al.,
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2009). Additionally, baseline AUTOC scores were not significantly related to selfreported average daily caffeine consumption contrary to what would be expected based
on previous attempts to measure caffeine dependence (Hughes et al., 1998; it is important
to note here that self-reported average daily caffeine consumption did not appear to vary
meaningfully in any statistical analyses using any variables in the current study). Thus the
AUTOC either does not effectively measure caffeine dependence or caffeine dependence
may change rapidly relative to dependence for other drugs such as nicotine (DiFranza et
al., 2009). Given the sparse literature on measuring dependence for caffeine further
research is necessary to define the construct. Stronger validity evidence may be gathered
for the AUTOC once the construct of interest is more clearly defined. Additionally, the
AUTOC may be adapted to more validly measure caffeine dependence: Items on the
AUTOC were derived from a measure of smoking dependence, a construct that may not
be as similar to caffeine dependence as originally hypothesized.
The majority of participants met criteria for abstinence during the BAT, which
allowed for caffeine withdrawal to be examined. CWS scores did not differ across
sessions as would be expected given the majority of participants experienced abstinence
(and thus withdrawal) at least once during the study. As predicted, SCEWS scores
significantly differed during the BAT when experience of abstinence was greatest among
the sample. However, CWS and SCEWS scores significantly correlated at all three time
points. The CWS was derived from a measure of smoking withdrawal that assessed
responses to experience of symptoms of withdrawal on a 5-point Likert scale. The
SCEWS was derived from lists of common symptoms of caffeine withdrawal in two
drugs text books to which respondents answer yes or no as to whether they were currently
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experiencing the symptoms. Interestingly, CWS scores significantly differed at both the
BAT and return to baseline between participants who reduced and did not reduce caffeine
use as evident by reduction of light transmittance by at least one SD derived from
duplicated saliva samples across all three sessions. SCEWS scores only significantly
differed at Baseline 2. It is conceivable that both the CWS and the SCEWS measure
experience of caffeine withdrawal to varying degrees such that the SCEWS may provide
more valid responses than the CWS. The current study provides preliminary evidence for
the utility of the CWS, and SCEWS; however, further validity evidence is necessary (e.g.,
using large sample sizes than the one used in the current study) before either the CWS or
the SCEWS may be used for clinical purposes.
It is important to develop sound measures of caffeine dependence and withdrawal
so that these constructs may be validly and reliably measured. Despite previous attempts
to characterize these constructs (Hughes et al., 1998; Juliano & Griffiths, 2004), currently
no such measures exist for caffeine dependence or withdrawal. Thus it is difficult to
determine the extent and severity of these phenomena. Likewise the potential utility of a
BAT may be fully realized only after problematic caffeine consumption (e.g., incidences
of caffeine dependence) is better characterized in order to identify individuals for whom
treatment would be beneficial. Additionally, valid measures of caffeine dependence and
withdrawal would allow for caffeine to serve as a model for studying dependence and
withdrawal phenomena in other drugs.
Given the promising results observed in the current study, future research should
examine CM of caffeine over a longer time period. Because caffeine consumption can be
experimentally manipulated, CM of caffeine may be useful for not only initiating but also
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reinforcing continued abstinence from caffeine beyond experience of peak withdrawal
symptoms, although the current results indicate such generalization of treatment
outcomes may supersede the need for continued reinforced abstinence. Long-term
compliance with the dietary changes associated with reduced caffeine use may be
optimally pursued through such methods (Griffiths & Reissig, 2008). Additionally, the
overall success observed in the current study using a sample of users of a wide range of
caffeine suggests similar research may be fruitful among other populations of interest
(e.g., users of high levels of caffeine, users advised to avoid caffeine). Specific aspects of
the BAT (e.g., payment amount) could be manipulated to determine optimally costeffective conditions for implementing CM for caffeine.
The current study showed caffeine use can be experimentally manipulated by a
CM procedure similarly to how many other drugs have been shown to do (e.g., alcohol,
Miller et al., 1974). These results indicate CM may be a viable avenue for treating
problematic caffeine consumption. Novel measures of caffeine dependence and
withdrawal provide a preliminary attempt to assess these phenomena. It is hopeful that
further research on treatment of caffeine consumption will allow for the measurement of
caffeine dependence and withdrawal so that individuals who need treatment may be
identified and have an empirically-based solution via CM.
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Table 1
Descriptive Statistics for Dependent Measures

Caffeine Latency (hr)
% Light Transmittance
AUTOC
CWS
SCEWS

Baseline 1
M
SD
7.11
10.14
85.57
6.38
8.72
5.99
64.38
6.77
3.05
3.04

BAT
M
54.23
79.58
10.62
65.26
5.00

SD
14.59
9.23
8.77
8.82
4.48

Baseline 2
M
SD
49.65
56.93
80.16
10.49
10.28
8.46
65.15
8.98
2.97
3.96

Note. N = 39. Caffeine Latency (hr) = self-reported latency since last consuming caffeine in
hours. AUTOC scores can range from 0 to 36 with higher scores indicative of greater caffeine
dependence. CWS scores can range from 23 to 115. SCEWS scores can range from 0 to 19.
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Table 2
Summary of Intercorrelations for AUTOC, CWS, and SCEWS

Measure
1. AUTOC1
2. AUTOC2
3. AUTOC3
4. CWS 1
5. CWS 2
6. CWS 3
7. SCEWS 1
8. SCEWS 2
9. SCEWS 3

1
–
.91**
.87**
.46**
.56**
.52**
.37*
.67**
.57**

2

3

4

5

6

7

8

9

–
.94**
.52**
.71**
.59**
.25
.75**
.50**

–
.60**
.77**
.72**
.34*
.78**
.64**

–
.75**
.73**
.36*
.38*
.50*

–
.85**
.29
.67**
.40*

–
.37*
.60**
.58**

–
.52**
.51**

–
.52**

–

Note. Intercorrelations for novel measures of caffeine dependence and withdrawal (N = 39) at
Baseline 1(1), BAT (2), and Baseline 2 (3).
*p < .05. **p < .01.
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Figure 1. Percentage of light transmittance at 450 nm. Lower levels of transmittance are
associated with lower levels of caffeine use.

35

Participants Who Met Abstinence Criteria
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Figure 2. Number of participants who met criteria for abstinence during each study
phase. No participants met criteria during Baseline 1, 37 participants met criteria during
the BAT, and 18 participants met criteria during Baseline 2 (N = 39).
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Appendix A
Informed Consent
Contingency Management of Caffeine Consumption Cessation (IRB#12-0199)
You may be eligible to participate in a study on caffeine consumption behavior. This study
is being conducted Dr. Jessica Irons, an assistant professor of psychology at James
Madison University along with Brad Joachim, a graduate student in psychology. Your
responses to a recent web-based survey indicate that you are a student at James Madison
University and you consume at least 25 mg caffeine per day. If either of these is incorrect,
please tell the researcher at this time.
Participation in this study is voluntary. If you decide to participate, you will sign this
informed consent form. Please ask any questions before you sign. If you choose to
participate in this study, you will complete several questionnaires and answer some
questions about your caffeine consumption today. You will also be asked to provide a
saliva sample, which is necessary to verify that your caffeine consumption level meets a
required level to participate in this study. This intake session will take approximately 20
minutes of your time, and you will be compensated for your participation with monetary
payment ($10).
The remainder of the study will last approximately 1 week. During the remainder of the
study you will be asked to attend the lab two more times in addition to today. During each
of these visits, you will be asked to provide a saliva sample and to complete a brief selfreport measure. Each of these visits will take approximately 15 minutes and will not exceed
30 minutes. Depending on the session, you may earn access to money depending on your
caffeine consumption behavior; however, you do NOT have to change your caffeine
consumption behavior to be enrolled in this study or to earn money in this study (i.e., you
may earn some money regardless of your caffeine consumption).
You will be compensated for your participation with monetary payment. Payments will be
made in lump sum following sample analysis, which will occur 1 – 3 days after the last
session of the study. Payment amounts will vary by session. In total, you may be able to
earn up to $45.00 over the course of the study. You will be compensated for attendance,
regardless of your caffeine consumption behavior. You are NOT required to change your
caffeine consumption behavior to participate in this study. If you choose to change your
caffeine consumption behavior, you may earn access to payment as a result. In the event
that you miss one scheduled session, you will be contacted to reschedule an appointment.
Should you miss more than two appointments throughout the study, you will be removed
from the study.
All responses will be confidential, and to maintain your privacy, your questionnaires will
be labeled by a code number that we assign to you. Your name will not be linked to your
data in any way. The master code list will be kept in a locked filing cabinet separate from
the data that is accessible only to the researcher. The master code list will be destroyed
after data analysis is complete. This informed consent will be destroyed after 3 years.
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The risks of participating in this intake session are minimal. You may find answering
questions about your use of caffeine distressing. Abstinence from caffeine consumption
may be associated with mild symptoms such as headache, drowsiness, fatigue, irritability,
or negative mood state. Breaches of confidentiality are highly unlikely because your
identifying information will be kept separately from the questionnaires that you complete,
and your questionnaires will be identified by your code number. You have the option to
withdraw your consent to participate at any point of this session. If you decide to withdraw
from the study you will not be penalized.
The direct benefit to you, the participant, is the opportunity to qualify for a study in
which you will have the opportunity to engage in brief caffeine consumption abstinence,
and you may be able to use the study as a way of initiating longer term caffeine
consumption abstinence. Potential to engage in brief substance is predictive of successful
longer term abstinence in the future. We cannot promise you that you will achieve either
short- or long-term abstinence from caffeine consumption. Your participation has the
potential to benefit the public by helping psychologists develop better methods of
substance use cessation.
Information collected through your participation may be published in a professional
journal, and/or presented at a professional psychology conference. However, your name
and any other identifying information will not be associated with the data collected, and
you will thus remain confidential.
_____ Participant’s Initials
Your decision whether or not to participate will not jeopardize your future relations with
James Madison University, or the Department of Psychology. If you have any further
questions or would like to receive a copy of the final aggregate results of this study,
please contact Dr. Jessica Irons (568-6565, ironsjg@jmu.edu, Department of
Psychology).
For more information regarding your rights as a research participant you may contact the
James Madison University IRB Chair, Dr. David Cockley (540-568-2834,
cocklede@jmu.edu).
HAVING READ THE INFORMATION PROVIDED YOU MUST DECIDE WHETHER
OR NOT YOU WISH TO PARTICIPATE IN THIS INTAKE SESSION. YOUR
SIGNATURE INDICATES YOUR WILLINGNESS TO PARTICIPATE.
By signing this form, I certify that I am at least 18 years of age.
________________________________
Participant's signature
Date

____________________________
Investigator's signature
Date

________________________________
Participant’s printed name

____________________________
Co-investigator's signature Date
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Appendix B
Demographics Questionnaire
Please answer the following questions as completely as you can to the best of your
ability.
Gender:
Female
Male
Age:
years
Race: (select all that apply)
Asian
Black or African American
White
Hispanic or Latino
American Indian or Alaska Native
Native Hawaiian or Other Pacific Islander
Multi-ethnic
Other
How many years of school have you completed (e.g., graduated high school = 12
years)?
__________
How regularly do you smoke (answer in days per week)?
__________
Do you suffer from any cardiovascular health problems?
Yes ______ No ______
Do you suffer from any medical conditions?
Yes ______ No ______
Do you have any diagnosed psychological/psychiatric conditions?
Yes ______ No ______
Do you currently take any prescription medications (please do not include birth
control when answering this question)?
Yes ______ No ______
Do you take any recreational drugs other than alcohol or nicotine?
Yes ______ No ______
Are you currently pregnant or attempting to get pregnant?
Yes ______ No ______
How regularly do you exercise (please answer in number of days per week)?
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__________ days per week
Are you particularly sensitive or allergic to the effects of caffeine?
Yes ______ No ______
Have you ever been advised to avoid caffeine?
Yes ______ No ______
What is your height (report in inches)?
__________ inches
What is your weight?
__________ lbs.
Please indicate how stressful you feel your daily life is on average (scale of 1-10, 1 =
not stressed at all, 10 = completely stressed):
_________

On average, how much expendable money (i.e., money that you can spend for
personal reasons – not bills, insurance, etc.) do you have per month?
$_________
Are you willing to be contacted about opportunities to participate in future studies
about caffeine consumption where you would have the opportunity to earn money
or gift certificates and coupons? ____ Yes
_____ No
If yes, are you willing to provide biological samples to verify your level of caffeine
consumption? These measures will be used ONLY to assess caffeine consumption
and ALL results will remain confidential. ____ Yes
_____ No

40
Appendix C
Daily Caffeine Consumption Questionnaire (DCCQ)
What is your most consumed source of caffeine? (e.g., coffee, tea, soft drinks, energy
drinks, chocolate, caffeinated gum)
____________________________________
How long has it been since you last consumed a caffeinated product?
____________________________________
How much caffeine did you consume then? (e.g., 2 cups of coffee, a 20 oz. bottle of soda,
a large iced tea from a restaurant)
____________________________________
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Appendix D
Autonomy Over Caffeine Scale (AUTOC)
Please indicate to what degree the following statements describe you:
1. When I go too long without a caffeinated product, I get impatient.
2. When I got too long without a caffeinated product, I get strong urges that are hard to get rid of.
3. When I go too long without a caffeinated product, I lose my temper more easily.
4. When I go too long without a caffeinated product, I get nervous or anxious.
5. I rely on caffeinated products to focus my attention.
6. I rely on caffeinated products to take my mind off being bored.
7. I rely on caffeinated products to deal with stress.
8. I would go crazy if i couldn't have a caffeinated product.
9. When I feel stressed, I want a caffeinated product.
10. When I see other people consuming caffeinated products, I want to do so as well.
11. When I smell a caffeinated product, I want to consume a caffeinated product.
12. While eating, I want to consume a caffeinated product.

Not at
all

A
little

Pretty
well

Very
well
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Appendix E
Caffeine Withdrawal Scale
Please answer the following questions based on how you
have felt or what you have noticed [over the last 24
hours/over the last week]. Answer based on how you have
felt in general during this time:
1. I am getting restful sleep
2. I have been tense or anxious.
3. My level of concentration is excellent
4. I awaken from sleep frequently during the night.
5. I have felt impatient.
6. I have felt upbeat and optimistic.
7. I have found myself worrying about my problems.
8. I have had frequent urges to consume caffeinated
products.
9. I have felt calm lately.
10. I have been bothered by the desire to consume
caffeinated products.
11. I have felt sad or depressed.
12. I have been irritable, easily angered.
13. I have been bothered by negative moods such as anger,
frustration, and irritability.
14. I am satisfied with my sleep.
15. I have felt frustrated.
16. I have felt hopeless or discouraged.
17. I have thought about consuming caffeinated products a
lot.
18. I feel that I am getting enough sleep.
19. It is hard to pay attention to things.
20. I have felt happy and content.
21. My sleep has been troubled
22. I have trouble getting caffeinated products off my mind.
23. It has been difficult to think clearly.

Strongly
Disagree

Disagree

Neither
Agree
nor
Disagree

Agree

Strongly
Agree
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Appendix F
Stimulant and Caffeine Experience of Withdrawal Symptoms
Indicate whether you have recently (i.e., in the previous couple hours)
experienced the following more so than you normally may experience each:
1. Headache
2. drowsiness
3. fatigue
4. negative mood state
5. impaired intellectual performance
6. impaired motor performance
7. difficulty with concentration
8. decreased energy
9. weakness
10. lethargy
11. decreased motivation for work
12. impaired concentration
13. increased irritability
14. flu-like symptoms (aches, muscle stiffness, hot/cold spells, nausea,
heavy feelings in the limbs)
15. vivid, unpleasant dreams
16. insomnia or hypersomnia
17. increased appetite
18. psychomotor retardation or agitation
19. experience of one of the above has caused significant distress or
impairment in social, occupational, or other important areas of
functioning

Yes

No
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Appendix G
Debriefing Statement
The purpose of this study was to examine an intervention designed to help individuals
reduce their caffeine consumption. If participation in this study caused you any
discomfort or distress, you should visit one of the following:
o Your personal general practitioner.
o University Health Center located next to Burruss Hall, at the corner of Mason and
Grace St, adjacent to Rockingham Memorial Hospital, (540.568.6178;
http://www.jmu.edu/healthctr/)
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